The company is investing $1 billion in its Songdo Bio Campus in South Korea, with Plant 1 scheduled for completion this year and full-scale commercial production by 2027.
By automating and digitizing critical processes, Ori’s platform is designed to streamline manufacturing workflows and overcome bottlenecks that limit patient access.
The Montreal-based company is at risk from potential tariffs from President Donald Trump and Canada’s government that could adversely affect its financial results.
Purdue’s Young Institute Pharmaceutical Manufacturing Consortium is working to address bottlenecks in efficiency, contamination control, and regulatory compliance.
Aragen Life Sciences stands to benefit as the biopharma industry looks to derisk its supply chains and shift outsourcing away from China to Indian service providers.
President Trump in an address to a joint session of Congress said the European Union and India, among other nations, charge “tremendously higher” tariffs on U.S. goods.
The company’s experience as a former RNA drug developer gives it a unique edge — it understands not just how to make RNA, but how to make it work in real-world applications.
The company said the regulatory approval secures reliable and consistent supply of Contrave, more than doubling its capacity to produce the medication.
Pharmaceutical manufacturing operates in a high-stakes environment where regulatory compliance, product integrity, and operational uptime are non-negotiable. As the industry becomes...
Discover the latest contract manufacturing key trends for the life science industry, including compliance, digital transformation and more. Don't let your organization fall behind...
As the life sciences sector evolves with personalized medicine, biologics, and digitalization, manufacturers must innovate, invest in advanced tech, and adopt agile manufacturing...
